s Cenobamate: New Antiseizure Medication with High Efficacy | Iris Publishers
Journal Flyer

Archives in Neurology & Neuroscience - ANN

ISSN: 2641-1911

Managing Editor: Grace Allan

NLM ID: 101759143

Contact us at:

Open Access Review Article

Cenobamate: New Antiseizure Medication with High Efficacy

Steve Chung*

Professor of Neurology, Banner University Medical Center-Phoenix University of Arizona-Phoenix, USA

Corresponding Author

Received Date: October 18, 2021;  Published Date: November 17, 2021

Abstract

Approximately 30% of epilepsy patients experience recurrent seizures despite many new antiseizure medications (ASMs) became available over the past 25 years. Cenobamate is a newest FDA approved ASM for the treatment of focal onset seizures in adults as both monotherapy and adjunctive therapy in November 2019 [1]. Pivotal clinical trials reported superior seizure improvement in patients with focal epilepsy.

Article Details
Citation

  • Steve Chung. Cenobamate: New Antiseizure Medication with High Efficacy. Arch Neurol & Neurosci. 11(5): 2021. ANN.MS.ID.000771.

Signup for Newsletter
  • newsletter-subscription
© 2018 Iris Publishers LLC, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use. Creative Commons License Open Access by
Iris Publishers LLC is licensed under Creative Commons License a Creative Commons Attribution 4.0 International License. Based on a work at www.irispublishers.com. Best viewed in browser_icons browser_icons | Above IE 9.0 version | Privacy Policy
Scroll to Top